MOR03087 (MOR202)
Showing 1 - 25 of 35
Multiple Myeloma Trial in Austria, Germany (MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone)
Completed
- Multiple Myeloma
- MOR03087 phase 1 dose escalation
- +4 more
-
Vienna, Austria
- +9 more
Nov 12, 2021
Glomerulonephritis, Membranous, antiPLA2R Positive Trial in Worldwide (MOR202)
Completed
- Glomerulonephritis, Membranous
- antiPLA2R Positive
-
Azusa, California
- +44 more
Dec 12, 2022
Immunoglobulin A (IgA) Nephropathy Trial in Worldwide (Felzartamab, Placebo)
Recruiting
- Immunoglobulin A (IgA) Nephropathy
- Felzartamab
- Placebo
-
Oxnard, California
- +59 more
Dec 12, 2022
Coronary Artery Disease Trial in Worldwide (Percutaneous coronary intervention)
Active, not recruiting
- Coronary Artery Disease
- Percutaneous coronary intervention
-
Epping, Australia
- +51 more
Dec 8, 2021
NASH - Nonalcoholic Steatohepatitis Trial in Worldwide (VK2809, Placebos)
Recruiting
- NASH - Nonalcoholic Steatohepatitis
- VK2809
- Placebos
-
Birmingham, Alabama
- +107 more
Mar 1, 2022
NSCLC Trial in Worldwide (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)
Active, not recruiting
- Non-small Cell Lung Cancer
- Pembrolizumab
- +2 more
-
Anchorage, Alaska
- +161 more
Oct 26, 2022
Pilot Study of Cardiac MR in Patients With Muscular Dystrophy
Recruiting
- Muscular Dystrophies
- +3 more
-
Washington, District of ColumbiaChildren's National Health System
Mar 1, 2022
Acute Myeloid Leukemia Trial in Worldwide (guadecitabine, Treatment Choice (TC))
Completed
- Acute Myeloid Leukemia
- guadecitabine
- Treatment Choice (TC)
-
Los Angeles, California
- +94 more
Sep 5, 2021
Urinary Bladder Tumors Trial in Worldwide (Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy
Recruiting
- Urinary Bladder Neoplasms
- Pembrolizumab
- +8 more
-
Washington, District of Columbia
- +120 more
Jan 19, 2023
Pulmonary Disease, Chronic Obstructive Trial in Worldwide (BEA 2180 BR, Tiotropium Bromide, Placebo)
Completed
- Pulmonary Disease, Chronic Obstructive
- BEA 2180 BR
- +2 more
-
Jasper, Alabama
- +177 more
Jul 30, 2021
Endometrial Cancer, Uterine Carcinosarcoma Trial in New York, Bethlehem, Milwaukee (Rucaparib, Bevacizumab, Atezolizumab)
Active, not recruiting
- Endometrial Cancer
- Uterine Carcinosarcoma
- Rucaparib
- +2 more
-
New York, New York
- +2 more
Apr 4, 2022
Clear Cell Renal Cell Carcinoma Trial in Worldwide (Belzutifan, Pembrolizumab, Placebo)
Recruiting
- Clear Cell Renal Cell Carcinoma
- Belzutifan
- +2 more
-
Duarte, California
- +250 more
Jan 27, 2023
Nonalcoholic Steatohepatitis Trial in Worldwide (Placebo, Cenicriviroc)
Terminated
- Nonalcoholic Steatohepatitis
- Placebo
- Cenicriviroc
-
Birmingham, Alabama
- +345 more
Feb 11, 2022
Myocardial Infarction Trial in Worldwide (Empagliflozin, Placebo)
Recruiting
- Myocardial Infarction
- Empagliflozin
- Placebo
-
Alexander City, Alabama
- +464 more
Aug 22, 2022
Metastatic Colorectal Cancer Trial in Worldwide (Xilonix, Placebo)
Acute Coronary Syndrome Trial in Worldwide (Milvexian, Placebo)
Not yet recruiting
- Acute Coronary Syndrome
- Milvexian
- Placebo
-
Alexander City, Alabama
- +862 more
Feb 23, 2023
cuTe Heart failUre:pRospective Echocardiographic and Clinical
Recruiting
- Heart Failure
- +3 more
- Transthoracic Echocardiography
-
Sydney, Australia
- +30 more
Jan 10, 2022
Acute Coronary Syndrome Trial in Worldwide (Apolipoprotein A-I [human] (apoA-I), Placebo)
Recruiting
- Acute Coronary Syndrome
- Apolipoprotein A-I [human] (apoA-I)
- Placebo
-
Alexander City, Alabama
- +930 more
Aug 8, 2022
Effective Management of Calcific Aortic Stenosis in the Elderly
Completed
- Calcific Aortic Stenosis
- (no location specified)
Aug 6, 2019
Pancreatic Ductal Carcinoma Trial in Worldwide (Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo,
Terminated
- Pancreatic Ductal Carcinoma
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
- +3 more
-
Mobile, Alabama
- +216 more
Jun 30, 2020